All Stories

  1. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist
  2. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer
  3. Incentive spirometry and positive expiratory pressure improve ventilation and recruitment in postoperative recovery: A randomized crossover study
  4. Intraparenchymal Renal Artery Pseudoaneurysm and Arteriovenous Fistula on a Solitary Kidney Occurring 38 Years after Blunt Trauma
  5. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy
  6. Castration-resistant Prostate Cancer: Adaptation or Clonal Selection? Insight from the EORTC 30891 Trial
  7. Will new AR inhibitors reshape the prostate cancer landscape?
  8. Diagnosis and Management of Metastatic Prostate Cancer
  9. Can we improve the definition of high‐risk, hormone naïve, non‐metastatic prostate cancer?
  10. Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy
  11. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?
  12. Landmarks in hormonal therapy for prostate cancer
  13. Epidemiology and Prevention of Prostate Cancer
  14. Toward the End of Blind Prostate Biopsies?
  15. Genitourinary Cancer
  16. Bone Scan Index made easy, at last
  17. Continuous Improvement Versus Innovation: The Case for Sipuleucel-T
  18. Chemoprevention of Prostate Cancer
  19. Hormone Therapy for Prostate Cancer: What Have We Done With Charles Huggins’ Legacy?
  20. Chairperson's introduction
  21. What is the pathophysiology of a hormone-resistant prostate tumour?
  22. Welcome
  23. Chemoprevention of prostate cancer with nutrients and supplements
  24. Chemoprevention of prostate cancer with nutrients and supplements
  25. Re: Pharmacological Prevention of Side Effects of Androgen Deprivation Therapy, A New Challenge?
  26. Prostate Cancer Management: What Does the Future Hold?
  27. Prostate Cancer, Depression, and Risk of Suicide: Should We Pay More Attention?
  28. Quand est-ce que je propose un blocage androgénique complet ?
  29. Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways
  30. Intermittent Androgen Deprivation Therapy: Conventional Wisdom versus Evidence
  31. Editorial Comment on: Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth
  32. The Motion: Hormonal Blockade Should be Limited Due to Significant Adverse Effects
  33. A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient
  34. What is New in Hormone Therapy for Prostate Cancer in 2007?
  35. The Importance of Testosterone Control in Prostate Cancer
  36. Optimal Testosterone Control and Eligard®
  37. Docetaxel and Beyond
  38. Advanced Prostate Cancer: Hormones and Beyond
  39. Eligard®: Advantages for Optimal Testosterone Control
  40. Severe Intraoperative Acute Compartment Syndrome with Bullous Eruption Complicating IV Fluid Administration
  41. Over- and Underdiagnosis of Prostate Cancer: The Dangers
  42. The role of endourology in ureteropelvic junction obstruction
  43. Apoptotic pathways in prostate cancer
  44. Intermittent endocrine treatment
  45. Thapsigargin induces a calmodulin/calcineurin‐dependent apoptotic cascade responsible for the death of prostatic cancer cells